Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the ...

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed to serving customers in this important market. For two decades, Illumina has been proud ...

Illumina (ILMN) has returned to profitability, reporting high quality earnings and trading at $123.54 per share, which is below its estimated fair value of $166.88. The company is forecasting EPS ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

In summary, Illumina’s earnings call reflects a company that is navigating challenges with strategic foresight and operational excellence. While there are hurdles in research markets and China, the ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...